The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Melatonin: an inhibitor of breast cancer
Open accessAbstract
The present review discusses recent work on melatonin-mediated circadian regulation, the metabolic and molecular signaling mechanisms that are involved in human breast cancer growth, and the associated consequences of circadian disruption by exposure to light at night (LEN). The anti-cancer actions of the circadian melatonin signal in human breast cancer cell lines and xenografts heavily involve MT 1 receptor-mediated mechanisms. In estrogen receptor alpha (ERα)-positive human breast cancer, melatonin suppresses ERα mRNA expression and ERα transcriptional activity via the MT 1 receptor. Melatonin also regulates the transactivation of other members of the nuclear receptor superfamily, estrogen-metabolizing enzymes, and the expression of core clock and clock-related genes. Furthermore, melatonin also suppresses tumor aerobic metabolism (the Warburg effect) and, subsequently, cell-signaling pathways critical to cell proliferation, cell survival, metastasis, and drug resistance. Melatonin demonstrates both cytostatic and cytotoxic activity in breast cancer cells that appears to be cell type-specific. Melatonin also possesses anti-invasive/anti-metastatic actions that involve multiple pathways, including inhibition of p38 MAPK and repression of epithelial–mesenchymal transition (EMT). Studies have demonstrated that melatonin promotes genomic stability by inhibiting the expression of LINE-1 retrotransposons. Finally, research in animal and human models has indicated that LEN-induced disruption of the circadian nocturnal melatonin signal promotes the growth, metabolism, and signaling of human breast cancer and drives breast tumors to endocrine and chemotherapeutic resistance. These data provide the strongest understanding and support of the mechanisms that underpin the epidemiologic demonstration of elevated breast cancer risk in night-shift workers and other individuals who are increasingly exposed to LEN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Phototransduction by retinal ganglion cells that set the circadian clock
Berson, D. M., Dunn, F. A., & Takao, M. (2002) · Science · doi:10.1126/science.1067262 · Cited by 3,629
International Journal of Oncology
(2026) · International Journal of Oncology · doi:10.3892/ijo · Cited by 2,331
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
Action Spectrum for Melatonin Regulation in Humans: Evidence for a Novel Circadian Photoreceptor
Brainard, G. C., Hanifin, J. P., Greeson, J. M., Byrne, B., Glickman, G., Gerner, E., & Rollag, M. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-06405.2001 · Cited by 1,930
Weinberg, R. A., & Weinberg, R. A. (2006) · W.W. Norton eBooks · doi:10.1201/9780203852569 · Cited by 1,751
Fantin, V. R., St-Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.023 · Cited by 1,635
Cited by
Melatonin Synthesis and Function: Evolutionary History in Animals and Plants
Zhao, D., Yu, Y., Shen, Y., Liu, Q., Zhao, Z., Sharma, R., & Reiter, R. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00249 · Cited by 689
Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas
Reiter, R. J., Rosales-Corral, S., Tan, D. X., Jou, M. J., Galano, A., & Xu, B. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2609-7 · Cited by 558
Rotating Night-Shift Work and the Risk of Breast Cancer in the Nurses' Health Studies
Wegrzyn, L. R., Tamimi, R. M., Rosner, B. A., Brown, S. B., Stevens, R. G., Eliassen, A. H., Laden, F., Willett, W. C., Hankinson, S. E., & Schernhammer, E. S. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx140 · Cited by 258
Minich, D. M., Henning, M., Darley, C., Fahoum, M., Schuler, C. B., & Frame, J. (2022) · Nutrients · doi:10.3390/nu14193934 · Cited by 176
Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin
Tascioglu Aliyev, A., Panieri, E., Stepanić, V., Gurer-Orhan, H., & Saso, L. (2021) · Molecules · doi:10.3390/molecules26071853 · Cited by 50
Metadata
- Authors
- Hill, S. M., Belancio, V. P., Dauchy, R. T., Xiang, S., Brimer, S., Mao, L., Hauch, A., Lundberg, P. W., Summers, W., Yuan, L., Frasch, T., & Blask, D. E.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2015-04-15
- Volume
- 22
- Issue
- 3
- Pages
- R183-R204
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2090740247
- Cited by
- 317
- References
- 173
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Melatonin: an inhibitor of breast cancer. https://app.cochat.ai/papers/10.1530/erc-15-0030
- The paper
- Hill, S. M., Belancio, V. P., Dauchy, R. T., Xiang, S., Brimer, S., Mao, L., Hauch, A., Lundberg, P. W., Summers, W., Yuan, L., Frasch, T., & Blask, D. E. (2015). Melatonin: an inhibitor of breast cancer. Endocrine-Related Cancer. https://doi.org/10.1530/erc-15-0030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
